Common questions about Эйлеа (FAQ)
Q: How is Эйлеа different from other eye injections used for similar conditions?
Official information describes Эйлеа as a recombinant fusion protein that acts as a decoy receptor. Its unique molecular action is designed to bind to two specific growth factors, VEGF-A and PlGF, which drive abnormal vessel growth and leakage. This dual binding mechanism distinguishes its molecular function from some other anti-VEGF agents that primarily target VEGF-A alone.
Q: Is Эйлеа considered a type of steroid or chemotherapy?
No, regulatory documents classify Эйлеа differently. It is categorized as a Vascular Endothelial Growth Factor (VEGF) Inhibitor and is also described as a recombinant fusion protein—a complex biologic medicine. It does not belong to the pharmacological classes of steroids or chemotherapy drugs.
Q: Does Эйлеа hurt when it's injected into the eye?
Official safety data indicates that Eye pain is a very common adverse reaction associated with the treatment procedure. To help minimize discomfort, the injection is performed by a physician who uses a local anesthetic. Any discomfort experienced is usually temporary, as reported in clinical settings.
Q: Can Эйлеа cause long-term damage to the eye?
The official safety profile is based primarily on clinical trial data, which often have follow-up periods of up to two years. Serious, though uncommon, risks are known to be associated with the injection procedure itself, such as infection or retinal detachment. Official documentation does not provide long-term safety data extending beyond the two-year period studied in pivotal trials.
Q: After an injection, when should I expect to see any difference in my vision?
The efficacy of the medicine in clinical trials was measured over long-term periods, typically at the one-year and two-year marks, based on mean changes in central vision. The official documentation does not specify a short-term or immediate expectation for noticeable changes in vision following a single injection.
Q: Can Эйлеа be used to treat 'floaters' in the eye?
The medicine is officially approved only for the treatment of specific retinal conditions like Wet AMD, DME, and RVO. Its labeling does not include the treatment of general vitreous floaters.
Q: Is there a maximum number of Эйлеа injections a person can receive?
Regulatory documents define the initial and maintenance dosing schedules for adults, which involve ongoing treatment to manage chronic eye conditions. However, the official product information does not specify a lifetime maximum number of injections.
Q: Can Эйлеа be used if I've already had cataract surgery?
A previous, uncomplicated cataract surgery is not listed as a contraindication or special precaution in the official regulatory safety profile. Notably, Cataract itself is listed as a common adverse reaction associated with the treatment.
Q: Is it safe to drive home after getting an Эйлеа injection?
Regulatory documents state that patients may experience temporary visual disturbances after the intravitreal injection and associated eye examinations. Due to this, caution is required, and driving or operating machinery should be avoided until vision has fully recovered.
Q: Does the vision improvement from Эйлеа last forever?
The drug is approved for the management of chronic conditions in the eye, and the dosing schedules require ongoing maintenance treatment to sustain the therapeutic effect. The official label does not claim a permanent cure or lifelong effect from the treatment.
Q: Is it normal for the eye to be red or feel gritty after the injection?
Yes, regulatory documents list Conjunctival hemorrhage (bleeding/redness on the white of the eye) and Eye pain as very common adverse reactions. Any resulting discomfort is also a commonly reported side effect that is typically temporary in nature.
Q: Is the injection procedure performed in an operating room?
The medicine is administered by a qualified physician in a controlled, aseptic clinical setting. Official regulatory documentation emphasizes the need for a sterile environment but does not require the procedure to take place in a surgical operating room.
Q: What is the average duration of the protective effect of one shot of Эйлеа?
For the maintenance phase in most adult conditions, the official recommended interval between injections is eight weeks (two months) for the standard dose. This interval is set to sustain the therapeutic effect achieved during the initial, more intensive phase.
Q: Can Эйлеа still be used if I have glaucoma?
Official documentation states that special caution is required for patients with poorly controlled glaucoma. If the pressure inside the eye is above a certain threshold, the treatment must be temporarily withheld.
Q: Does getting Эйлеа affect my ability to get other medical procedures like MRIs or X-rays?
Эйлеа is a protein-based medicine that is administered locally into the eye, resulting in minimal systemic exposure. Official regulatory labeling contains no documented warnings, contraindications, or required precautions regarding any interaction with diagnostic imaging procedures such as MRIs or X-rays.
Q: Is Эйлеа treatment available through government health programs?
Official information does not address payment or coverage. However, support resources, such as Patient Assistance Programs, may be available to help patients with access to the medicine, though eligibility rules apply.
Q: How do researchers measure the success of Эйлеа in clinical trials?
Success in pivotal trials was primarily tracked over one-to-two-year periods using two key measurements: changes in central vision acuity (how well a person can see) and changes in central retinal thickness or macular swelling (an anatomical measurement of fluid reduction).
Q: Are there different doses of Эйлеа used for different eye problems?
Yes, official regulatory documents indicate that the standard adult dose is 2 mg for conditions like Wet AMD and DME. However, official documentation indicates that a different dose is required for the treatment of Retinopathy of Prematurity (ROP) in premature infants.
Q: Can Эйлеа interact with herbal remedies or over-the-counter medicines?
Because Эйлеа is administered directly into the eye, the amount that enters the bloodstream is minimal, meaning the probability of typical drug-drug interactions is considered low. Official regulatory information notes that formal studies on interactions with herbal remedies or non-prescription medicines are generally not available.
Q: What is the risk of developing an eye infection after the Эйлеа injection?
The serious adverse reaction of Endophthalmitis (a serious infection inside the eye) has been reported following intravitreal injections, including those with Эйлеа. The procedure is required to be performed under strictly controlled, sterile conditions to help minimize this potential risk.
Q: Do studies suggest Эйлеа works better for certain age groups?
The official label explicitly states that no dose adjustment is required for older adult patients. Efficacy and safety data in the pivotal trials were collected across the broad adult population without indicating that the medicine works better for one specific age group.
Q: Is there a generic version of Эйлеа available?
Эйлеа is a biologic medicine, and the possibility of a generic version is covered by biosimilar pathways in regulatory bodies like the FDA and EMA. As such, biosimilar products for Aflibercept may be approved or under review by regulatory bodies (e.g., FDA/EMA), following established pathways for biologic medicines.
Q: Does the treatment stop working over time (tachyphylaxis)?
Official regulatory documents do not use the specific term 'tachyphylaxis' (treatment stopping working over time). They do note that the fixed dosing schedules used in initial trials may not fully represent patient outcomes in routine care, and some patients may require a return to more frequent dosing after an extended interval.
Q: Does Эйлеа cure the underlying eye condition, or just manage it?
The drug is used to manage chronic eye conditions that typically require ongoing, repeated treatment rather than a single-time cure. Its mechanism focuses on the suppression of pathological angiogenesis and the overall goal is to stabilize the eye environment.
Q: How does the mechanism of action in Эйлеа differ from Lucentis or Avastin?
Official regulatory documents define Эйлеа's mechanism by its unique binding to VEGF-A and PlGF, acting as a fusion protein decoy receptor. This differs from other common anti-VEGF agents that are typically monoclonal antibody fragments (Fab or full-length) that primarily target VEGF-A alone.
Q: What is the evidence about Эйлеа use in patients with diabetes?
Эйлеа is officially approved for the treatment of two conditions frequently seen in people with diabetes: Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR). The evidence supporting this use is derived from dedicated Phase 3 Randomized Controlled Trials.
Q: Can Эйлеа be used in both eyes at the same appointment?
For most adult indications, each vial or syringe is intended for single use only for the treatment of a single eye. However, for the pediatric indication of Retinopathy of Prematurity (ROP), the label specifically states that the injection may be administered bilaterally (in both eyes) on the same day.
Q: What does 'vascular endothelial growth factor' (VEGF) mean in simple terms?
VEGF stands for Vascular Endothelial Growth Factor, which is a naturally occurring protein in the body. Official patient information describes it as a signal that encourages the growth of blood vessels. When this protein is overactive in the eye, it can lead to the growth of abnormal, leaky vessels that cause vision problems.
Q: What should I report to my doctor immediately after the injection?
Official regulatory information advises patients to report, without delay, any symptoms that might suggest a serious adverse event, such as an infection or retinal detachment. Key symptoms to report include any new or sudden eye pain, eye redness, increased light sensitivity, or any significant change or blurring of vision.
